Balance Sheet
Accounts PayablesCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dr Reddys Laboratories (RDY) Non-Current Assets: 2018-2025

  • Dr Reddys Laboratories' Non-Current Assets rose 69.99% to $2.8 billion in Q1 2025 from the same period last year, while for Mar 2025 it was $2.8 billion, marking a year-over-year increase of 69.99%. This contributed to the annual value of $2.8 billion for FY2025, which is 69.99% up from last year.
  • According to the latest figures from Q1 2025, Dr Reddys Laboratories' Non-Current Assets is $2.8 billion, which was up 69.99% from $1.7 billion recorded in Q1 2024.
  • Dr Reddys Laboratories' 5-year Non-Current Assets high stood at $2.8 billion for Q1 2025, and its period low was $1.4 billion during Q1 2023.
  • Its 3-year average for Non-Current Assets is $2.0 billion, with a median of $1.7 billion in 2024.
  • Per our database at Business Quant, Dr Reddys Laboratories' Non-Current Assets dropped by 8.73% in 2022 and then skyrocketed by 69.99% in 2025.
  • Dr Reddys Laboratories' Non-Current Assets (Quarterly) stood at $1.6 billion in 2021, then declined by 8.73% to $1.5 billion in 2022, then fell by 4.44% to $1.4 billion in 2023, then climbed by 19.67% to $1.7 billion in 2024, then surged by 69.99% to $2.8 billion in 2025.
  • Its Non-Current Assets was $2.8 billion in Q1 2025, compared to $1.7 billion in Q1 2024 and $1.4 billion in Q1 2023.